Sponsor-Investigators

John Quigley

BTCRC-AML17-113

Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113

Status

Open to Accrual

Cancer Types

Leukemia

Locations

Fred & Pamela Buffett Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Illinois Cancer Center